BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-98@pharmaconomics
DTSTAMP:20260707T003512Z
DTSTART;VALUE=DATE:20260915
DTEND;VALUE=DATE:20260916
SUMMARY:BAYRY Phase 2 — BAY2599023 (DTX201)
DESCRIPTION:Phase 2 trial results for BAY2599023 (DTX201) in Hemophilia A are due Sep 15\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://clinicaltrials.gov/study/NCT03588299\n\nTrack it: https://pharmaconomics.com/e/98
URL:https://pharmaconomics.com/e/98
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:BAYRY catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR